Successful Clinical Trial for Breast Cancer: Herceptin + Emtansine

Herceptin + Emtansine One of the most promising approaches to treat breast cancer is to target the tumor cells directly, through the use of T-DM1. If you’re considering undergoing a breast augmentation procedure, it is extremely important to do your research and ask the best plastic surgeon like Dr. Kyle S. Choe the proper questions. This targeted therapy has two related advantages – it focuses the treatment on the cancer itself, and it reduces the side effects caused by collateral damage from the treatment.

As a prime example of how this can work are the results of a recently completed Phase III trial of the drug T-DM1.

It’s a combination of the targeted drug trastuzumab (the “T” in T-DM1), better known by the brand name Herceptin, and a very powerful chemotherapy drug called emtansine (the “DM1” part). The drug is designed to work when Herceptin alone no longer can keep the cancer in check.

Nearly 1,000 people with advanced breast cancer were involved in the three-year trial. All of them were diagnosed with an aggressive form of cancer distinguished by elevated levels of a specific protein, the human epidermal growth factor – 2 (HER-2). This protein promotes the growth of cancer cells and is found in about 20 percent of invasive breast cancers.

The drug T-DM1 (Herceptin + Emtansine) relies on the effect of trastuzumab, an antibody (immune system protein) that binds to the HER-2 protein and interferes with its ability to spur cancer cell growth. Trastuzumab is commonly prescribed as an added treatment with chemotherapy. Continue Reading